We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.
- Authors
Du, Lijun; Zhang, Lei; Li, Ling; Li, Xin; Yan, Jiaqin; Wang, Xinhua; Fu, Xiaorui; Sun, Zhenchang; Zhang, Xudong; Li, Zhaoming; Wu, Jingjing; Yu, Hui; Chang, Yu; Zhou, Zhiyuan; Nan, Feifei; Wu, Xiaolong; Tian, Li; Zhang, Mingzhi
- Abstract
Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is a specific subtype of peripheral T cell lymphoma (PTCL) with a poor prognosis. To date, there exist no standard therapeutic regimens for relapsed/refractory (R/R) ENKTL. More potent treatment strategies are urgently needed to improve the survival of these patients with R/R ENKTL. Herein, we present three R/R ENKTL patients who failed prior therapies (L-asparaginase containing chemotherapy, radiotherapy or biological-cell therapy, etc.) benefited from the combination regimen comprised of anti-programmed-death-1 (PD-1) antibody toripalimab, chidamide, etoposide, and thalidomide. They received the treatment regimen continuously until the disease progression occurs. As of data collection, two patients achieved complete remission (CR) after 4, 6 cycles of treatment, respectively, and another patient was evaluated as partial remission (PR) after 2 cycles. Treatment-related adverse events (AEs) mainly presented grade 2∼ 3 leukocytopenia and anemia, which were controllable. It follows that PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) regimen may be a promising choice for patients with R/R ENKTL and warrants further investigation.
- Subjects
PROGRAMMED cell death 1 receptors; THALIDOMIDE; CUTANEOUS T-cell lymphoma; LYMPHOMAS; ETOPOSIDE; IMMUNOGLOBULINS
- Publication
OncoTargets & Therapy, 2020, Vol 13, p7189
- ISSN
1178-6930
- Publication type
Article
- DOI
10.2147/OTT.S262039